ImevaX GmbH:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ImevaX GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11302
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ImevaX GmbH (ImevaX) is a biopharmaceutical company that develops novel vaccines to prevent chronic and nosocomial infections. Its lead product candidate IMX101, an immune evasion vaccine, is indicated for the treatment of Helicobacter pylori. Its pipeline products include IMA101 mucosal adjuvant that directs the immune response to the site of a Helicobacter pylori infection; IMD101, a diagnostic test for helicobacter pylori infection and pathogenicity. H. pylori depend on a bacterial factor to weaken the host immune system, which allows it to colonize the intestine. The vaccine disables the bacterial factor, enabling the body’s immune system to identify, fight and eliminate the bacteria. The company identifies and uses immune modulatory bacterial factors to develop specific vaccines. ImevaX is headquartered in Munich, Germany.

ImevaX GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ImevaX GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ImevaX GmbH, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
ImevaX Raises Funds through Second Tranche of Series A Financing 10
ImevaX Raises USD9.5 Million in Series A Venture Financing 11
Partnerships 12
ProJect Pharmaceutics Enters into Development Agreement with ImevaX for IMX101 12
ImevaX GmbH – Key Competitors 13
ImevaX GmbH – Key Employees 14
ImevaX GmbH – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
ImevaX GmbH, Pharmaceuticals & Healthcare, Key Facts 2
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ImevaX GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ImevaX GmbH, Deals By Therapy Area, 2012 to YTD 2018 8
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ImevaX Raises Funds through Second Tranche of Series A Financing 10
ImevaX Raises USD9.5 Million in Series A Venture Financing 11
ProJect Pharmaceutics Enters into Development Agreement with ImevaX for IMX101 12
ImevaX GmbH, Key Competitors 13
ImevaX GmbH, Key Employees 14

List of Figures
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[ImevaX GmbH:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pioneer Corp:企業の戦略的SWOT分析
    Pioneer Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Gliknik Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Gliknik Inc (Gliknik) is a biopharmaceutical company that develops therapies for patients suffering from cancer and immune disorders. The company’s pipeline products include biropepimut-S (GL-0817) and GL-2045. Its biropepimut-S is an engineered peptide immunomodulator targeted against impor …
  • Bajaj Allianz General Insurance Company Limited:企業の戦略・SWOT・財務情報
    Bajaj Allianz General Insurance Company Limited - Strategy, SWOT and Corporate Finance Report Summary Bajaj Allianz General Insurance Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • Aruba Networks, Inc.:企業の戦略・SWOT・財務情報
    Aruba Networks, Inc. - Strategy, SWOT and Corporate Finance Report Summary Aruba Networks, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Peter MacCallum Cancer Centre:製薬・医療:M&Aディール及び事業提携情報
    Summary Peter MacCallum Cancer Centre (Peter Mac) is a provider of public health services. It serves as a cancer research, treatment and education centre. The centre provides wide range of services including diagnostic, radiation therapy, treatment, cancer information and support services. It works …
  • Elong Inc
    Elong Inc - Strategy, SWOT and Corporate Finance Report Summary Elong Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • American Municipal Power Inc:企業の戦略的SWOT分析
    American Municipal Power Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • The Reject Shop Ltd (TRS):企業の財務・戦略的SWOT分析
    The Reject Shop Ltd (TRS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Electric Power Development Co Ltd (9513):企業の財務・戦略的SWOT分析
    Electric Power Development Co Ltd (9513) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Rizzani De Eccher S.P.A.:企業の戦略・SWOT・財務分析
    Rizzani De Eccher S.P.A. - Strategy, SWOT and Corporate Finance Report Summary Rizzani De Eccher S.P.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Europa Oil & Gas (Holdings) Plc (EOG):石油・ガス:M&Aディール及び事業提携情報
    Summary Europa Oil & Gas (Holdings) Plc (Europa Oil) is an oil and gas company that offers exploration and development services. The company's services include production and development of conventional and unconventional hydrocarbon assets. It operates its assets in East Midlands basin, Aquitain ba …
  • Themis Bioscience GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Themis Bioscience GmbH (Themis Bioscience) is a biotechnology company that develops prophylactic vaccines for emerging tropical infections. The company develops emerging and specialist indications and vaccines from preclinical to late-stage clinical development phases. It develops novel vacc …
  • Parsons Corporation:企業の戦略・SWOT・財務分析
    Parsons Corporation - Strategy, SWOT and Corporate Finance Report Summary Parsons Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Famy Care Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Famy Care Ltd (Famy Care) is a healthcare products provider that research, develops and manufactures female reproductive health care products. The company manufactures hormonal and reproductive health care products including famy care. Its hormonal formulation products include combined oral …
  • Horizon Discovery Group Plc (HZD):製薬・医療:M&Aディール及び事業提携情報
    Summary Horizon Discovery Group Plc (Horizon Discovery) is a life science company that discovers and develops genetically-modified cell lines using a proprietary translational genomics platform. The company offers products such as cell lines, reference standards and in vivo models. It also offers se …
  • Valero Energy Corp (VLO):石油・ガス:M&Aディール及び事業提携情報
    Summary Valero Energy Corp (Valero) is a downstream company that manufactures and markets transportation fuels and petrochemical products. The company’s assets include petroleum refineries, ethanol plants and renewable diesel production from a joint venture. Its refineries produce gasoline, diesel, …
  • CBR Systems Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CBR Systems Inc (CBR), a subsidiary of AMAG Pharmaceuticals Inc, is a stem cell company that offers new born stem cells. The company provides collection, processing, and long-term cryopreservation services for newborn umbilical cord blood stem cells and cord tissue units. It offers cord bloo …
  • Legend Holdings Corporation (3396):企業の財務・戦略的SWOT分析
    Legend Holdings Corporation (3396) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • CytImmune Sciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CytImmune Sciences Inc (CytImmune) is a clinical stage nanomedicine company that discovers, develops, and commercializes tumor-targeted therapies. The company develops nanotherapy platform, Aurimune, a tumor-targeted trojan horse. Its Aurimune binds TNF receptors on blood vessel cells at the …
  • Vallourec SA:戦略・SWOT・企業財務分析
    Vallourec SA - Strategy, SWOT and Corporate Finance Report Summary Vallourec SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆